Esogress-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and related motility disturbances. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and reducing acid-related irritation in the esophagus and stomach. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and symptom control. Esogress-L Capsule SR is indicated for the treatment of functional dyspepsia, erosive esophagitis, and GERD with associated motility disorders. It is contraindicated in patients with known hypersensitivity to either component and should be used cautiously in individuals with hepatic impairment. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Clinical monitoring is advised to assess therapeutic response and detect potential side effects. This combination therapy offers a synergistic approach to managing complex upper gastrointestinal conditions by addressing both acid suppression and motility enhancement.